Joseph R. Walker

4.4k total citations · 3 hit papers
27 papers, 3.1k citations indexed

About

Joseph R. Walker is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Joseph R. Walker has authored 27 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cardiology and Cardiovascular Medicine, 10 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Surgery. Recurrent topics in Joseph R. Walker's work include Antiplatelet Therapy and Cardiovascular Diseases (12 papers), Diabetes Treatment and Management (10 papers) and Lipoproteins and Cardiovascular Health (9 papers). Joseph R. Walker is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (12 papers), Diabetes Treatment and Management (10 papers) and Lipoproteins and Cardiovascular Health (9 papers). Joseph R. Walker collaborates with scholars based in United States, Germany and Sweden. Joseph R. Walker's co-authors include Jessica L. Mega, Elliott M. Antman, Marc S. Sabatine, Sandra Close, Stephen D. Wiviott, Eugene Braunwald, John T. Brandt, William L. Macias, Richard D. Hockett and Lei Shen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Joseph R. Walker

26 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

2008 1.7k citations Jessica L. Mega, Sandra Close et al. New England Journal of Medicine profile →
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel

2009 467 citations Jessica L. Mega, Sandra Close et al. Circulation profile →
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

2010 437 citations Jessica L. Mega, Sandra Close et al. The Lancet profile →

Peers

Joseph R. Walker

CCM

SURGE

EDM

PHARM

Nagy A. Farid United States

Sandra Close United States

Christopher D. Payne United States

Dietmar Trenk Germany

C. Steven Ernest United States

Farzin Beygui France

Guillaume Cayla France

Renli Teng United States

Tanja Morath Germany

Jochem W. van Werkum Netherlands

Nagy A. Farid United States

Joseph R. Walker

3.0k ×1.2

CCM

1.3k ×1.1

SURGE

669 ×0.9

EDM

908 ×1.5

PHARM

718 ×1.3

Citations per year, relative to Joseph R. Walker Joseph R. Walker (= 1×) peers Nagy A. Farid

Countries citing papers authored by Joseph R. Walker

Since Specialization

Citations

This map shows the geographic impact of Joseph R. Walker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph R. Walker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph R. Walker more than expected).

Fields of papers citing papers by Joseph R. Walker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph R. Walker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph R. Walker. The network helps show where Joseph R. Walker may publish in the future.

Co-authorship network of co-authors of Joseph R. Walker

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph R. Walker. A scholar is included among the top collaborators of Joseph R. Walker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph R. Walker. Joseph R. Walker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vandell, Alexander G., Joseph R. Walker, Karen Brown, et al.. (2017). Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 103(22). 1800–1805. 16 indexed citations

Vandell, Alexander G., et al.. (2016). An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. The Pharmacogenomics Journal. 18(1). 153–159. 29 indexed citations

Mega, Jessica L., Joseph R. Walker, Christian T. Ruff, et al.. (2015). Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. The Lancet. 385(9984). 2280–2287. 140 indexed citations

He, Ling, et al.. (2014). Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. Diabetes Research and Clinical Practice. 104(3). 401–409. 12 indexed citations

Bergmeijer, Thomas O., Udaya S. Tantry, Jurriën M. ten Berg, et al.. (2014). The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thrombosis and Haemostasis. 112(9). 589–597. 24 indexed citations

James, Stefan, Suman Duvvuru, Joseph A. Jakubowski, et al.. (2014). Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thrombosis and Haemostasis. 112(5). 943–950. 13 indexed citations

Ferreiro, José Luis, Joseph A. Jakubowski, Mark B. Effron, et al.. (2013). Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thrombosis and Haemostasis. 110(12). 1223–1231. 15 indexed citations

Tokuhiro, Shinya, Akira Shinagawa, Joseph R. Walker, et al.. (2012). Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure. Journal of Human Genetics. 57(8). 531–544. 6 indexed citations

Erlinge, David, Stefan James, Suman Duvvuru, et al.. (2012). TCT-725 Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel With High Accuracy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology. 60(17). B211–B212. 1 indexed citations

10.

Mega, Jessica L., Sandra Close, Stephen D. Wiviott, et al.. (2011). Abstract 11255: PON1 Q192R (rs662) Genetic Variant and Response to Clopidogrel and Prasugrel. Circulation. 124. 101–12. 1 indexed citations

11.

Kastrissios, Helen, Joseph R. Walker, Timothy J. Carrothers, et al.. (2011). Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites. The Journal of Clinical Pharmacology. 52(3). 404–415. 3 indexed citations

12.

Kelly, Ronan P., Sandra Close, Nagy A. Farid, et al.. (2011). Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. British Journal of Clinical Pharmacology. 73(1). 93–105. 42 indexed citations

13.

Mega, Jessica L., Sandra Close, Stephen D. Wiviott, et al.. (2010). ABCB1 GENETIC VARIANTS, PHARMACODYNAMIC RESPONSE, AND CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH CLOPIDOGREL AND PRASUGREL. Journal of the American College of Cardiology. 55(10). A113.E1056–A113.E1056. 4 indexed citations

14.

Mega, Jessica L., Sandra Close, Stephen D. Wiviott, et al.. (2010). Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. The Lancet. 376(9749). 1312–1319. 437 indexed citations breakdown →

15.

Walker, Joseph R., Karen Brown, Shashank Rohatagi, et al.. (2009). Quantitative Structure‐Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol). The Journal of Clinical Pharmacology. 49(10). 1185–1195. 13 indexed citations

16.

Brown, Karen, Joseph R. Walker, Robert J. Noveck, et al.. (2009). Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide. The Journal of Clinical Pharmacology. 50(5). 554–565. 22 indexed citations

17.

Hong, Ying, Shashank Rohatagi, Bahru Habtemariam, et al.. (2008). Population Exposure‐Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology. 48(6). 696–707. 35 indexed citations

18.

Mega, Jessica L., Sandra Close, Stephen D. Wiviott, et al.. (2008). Cytochrome P-450 Polymorphisms and Response to Clopidogrel. New England Journal of Medicine. 360(4). 354–362. 1725 indexed citations breakdown →

19.

Terra, Steven G., Daniel Pauly, Craig R. Lee, et al.. (2005). β-adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure*. Clinical Pharmacology & Therapeutics. 77(3). 127–137. 89 indexed citations

20.

Walker, Joseph R.. (1999). Antihypertensive agents. Journal of PeriAnesthesia Nursing. 14(5). 278–283. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact